Rituximab and lupus interstitial lung disease: friend or foe?
Identifieur interne : 000153 ( Ncbi/Curation ); précédent : 000152; suivant : 000154Rituximab and lupus interstitial lung disease: friend or foe?
Auteurs : Petros Efthimiou ; Manil Kukar ; Alissa HershSource :
- International journal of rheumatic diseases [ 1756-185X ] ; 2011.
Descripteurs français
- KwdFr :
- Acide mycophénolique (analogues et dérivés), Acide mycophénolique (usage thérapeutique), Adulte, Anticorps monoclonaux d'origine murine (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Association de médicaments, Dyspnée (physiopathologie), Dyspnée (traitement médicamenteux), Dyspnée (étiologie), Facteurs immunologiques (usage thérapeutique), Glucocorticoïdes (usage thérapeutique), Humains, Hydroxychloroquine (usage thérapeutique), Lupus érythémateux disséminé (), Lupus érythémateux disséminé (traitement médicamenteux), Mâle, Pneumopathies interstitielles (physiopathologie), Pneumopathies interstitielles (traitement médicamenteux), Pneumopathies interstitielles (étiologie), Prednisolone (usage thérapeutique), Rituximab, Résultat thérapeutique, Syndrome de Gougerot-Sjögren (), Syndrome de Gougerot-Sjögren (traitement médicamenteux), Tests de la fonction respiratoire.
- MESH :
- analogues et dérivés : Acide mycophénolique.
- physiopathologie : Dyspnée, Pneumopathies interstitielles.
- traitement médicamenteux : Dyspnée, Lupus érythémateux disséminé, Pneumopathies interstitielles, Syndrome de Gougerot-Sjögren.
- usage thérapeutique : Acide mycophénolique, Anticorps monoclonaux d'origine murine, Antirhumatismaux, Facteurs immunologiques, Glucocorticoïdes, Hydroxychloroquine, Prednisolone.
- étiologie : Dyspnée, Pneumopathies interstitielles.
- Adulte, Association de médicaments, Humains, Lupus érythémateux disséminé, Mâle, Rituximab, Résultat thérapeutique, Syndrome de Gougerot-Sjögren, Tests de la fonction respiratoire.
English descriptors
- KwdEn :
- Adult, Antibodies, Monoclonal, Murine-Derived (therapeutic use), Antirheumatic Agents (therapeutic use), Drug Therapy, Combination, Dyspnea (drug therapy), Dyspnea (etiology), Dyspnea (physiopathology), Glucocorticoids (therapeutic use), Humans, Hydroxychloroquine (therapeutic use), Immunologic Factors (therapeutic use), Lung Diseases, Interstitial (drug therapy), Lung Diseases, Interstitial (etiology), Lung Diseases, Interstitial (physiopathology), Lupus Erythematosus, Systemic (complications), Lupus Erythematosus, Systemic (drug therapy), Male, Mycophenolic Acid (analogs & derivatives), Mycophenolic Acid (therapeutic use), Prednisolone (therapeutic use), Respiratory Function Tests, Rituximab, Sjogren's Syndrome (complications), Sjogren's Syndrome (drug therapy), Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : Mycophenolic Acid.
- chemical , therapeutic use : Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents, Glucocorticoids, Hydroxychloroquine, Immunologic Factors, Mycophenolic Acid, Prednisolone.
- complications : Lupus Erythematosus, Systemic, Sjogren's Syndrome.
- drug therapy : Dyspnea, Lung Diseases, Interstitial, Lupus Erythematosus, Systemic, Sjogren's Syndrome.
- etiology : Dyspnea, Lung Diseases, Interstitial.
- physiopathology : Dyspnea, Lung Diseases, Interstitial.
- Adult, Drug Therapy, Combination, Humans, Male, Respiratory Function Tests, Rituximab, Treatment Outcome.
DOI: 10.1111/j.1756-185X.2010.01592.x
PubMed: 21303472
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000381
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000381
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000362
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000153
Links to Exploration step
pubmed:21303472Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rituximab and lupus interstitial lung disease: friend or foe?</title><author><name sortKey="Efthimiou, Petros" sort="Efthimiou, Petros" uniqKey="Efthimiou P" first="Petros" last="Efthimiou">Petros Efthimiou</name></author><author><name sortKey="Kukar, Manil" sort="Kukar, Manil" uniqKey="Kukar M" first="Manil" last="Kukar">Manil Kukar</name></author><author><name sortKey="Hersh, Alissa" sort="Hersh, Alissa" uniqKey="Hersh A" first="Alissa" last="Hersh">Alissa Hersh</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21303472</idno><idno type="pmid">21303472</idno><idno type="doi">10.1111/j.1756-185X.2010.01592.x</idno><idno type="wicri:Area/PubMed/Corpus">000381</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000381</idno><idno type="wicri:Area/PubMed/Curation">000381</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000381</idno><idno type="wicri:Area/PubMed/Checkpoint">000362</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000362</idno><idno type="wicri:Area/Ncbi/Merge">000153</idno><idno type="wicri:Area/Ncbi/Curation">000153</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rituximab and lupus interstitial lung disease: friend or foe?</title><author><name sortKey="Efthimiou, Petros" sort="Efthimiou, Petros" uniqKey="Efthimiou P" first="Petros" last="Efthimiou">Petros Efthimiou</name></author><author><name sortKey="Kukar, Manil" sort="Kukar, Manil" uniqKey="Kukar M" first="Manil" last="Kukar">Manil Kukar</name></author><author><name sortKey="Hersh, Alissa" sort="Hersh, Alissa" uniqKey="Hersh A" first="Alissa" last="Hersh">Alissa Hersh</name></author></analytic><series><title level="j">International journal of rheumatic diseases</title><idno type="eISSN">1756-185X</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Monoclonal, Murine-Derived (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Dyspnea (drug therapy)</term><term>Dyspnea (etiology)</term><term>Dyspnea (physiopathology)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunologic Factors (therapeutic use)</term><term>Lung Diseases, Interstitial (drug therapy)</term><term>Lung Diseases, Interstitial (etiology)</term><term>Lung Diseases, Interstitial (physiopathology)</term><term>Lupus Erythematosus, Systemic (complications)</term><term>Lupus Erythematosus, Systemic (drug therapy)</term><term>Male</term><term>Mycophenolic Acid (analogs & derivatives)</term><term>Mycophenolic Acid (therapeutic use)</term><term>Prednisolone (therapeutic use)</term><term>Respiratory Function Tests</term><term>Rituximab</term><term>Sjogren's Syndrome (complications)</term><term>Sjogren's Syndrome (drug therapy)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide mycophénolique (analogues et dérivés)</term><term>Acide mycophénolique (usage thérapeutique)</term><term>Adulte</term><term>Anticorps monoclonaux d'origine murine (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Association de médicaments</term><term>Dyspnée (physiopathologie)</term><term>Dyspnée (traitement médicamenteux)</term><term>Dyspnée (étiologie)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Humains</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Lupus érythémateux disséminé ()</term><term>Lupus érythémateux disséminé (traitement médicamenteux)</term><term>Mâle</term><term>Pneumopathies interstitielles (physiopathologie)</term><term>Pneumopathies interstitielles (traitement médicamenteux)</term><term>Pneumopathies interstitielles (étiologie)</term><term>Prednisolone (usage thérapeutique)</term><term>Rituximab</term><term>Résultat thérapeutique</term><term>Syndrome de Gougerot-Sjögren ()</term><term>Syndrome de Gougerot-Sjögren (traitement médicamenteux)</term><term>Tests de la fonction respiratoire</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Mycophenolic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Murine-Derived</term><term>Antirheumatic Agents</term><term>Glucocorticoids</term><term>Hydroxychloroquine</term><term>Immunologic Factors</term><term>Mycophenolic Acid</term><term>Prednisolone</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Acide mycophénolique</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lupus Erythematosus, Systemic</term><term>Sjogren's Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyspnea</term><term>Lung Diseases, Interstitial</term><term>Lupus Erythematosus, Systemic</term><term>Sjogren's Syndrome</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyspnea</term><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Dyspnée</term><term>Pneumopathies interstitielles</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyspnea</term><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dyspnée</term><term>Lupus érythémateux disséminé</term><term>Pneumopathies interstitielles</term><term>Syndrome de Gougerot-Sjögren</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide mycophénolique</term><term>Anticorps monoclonaux d'origine murine</term><term>Antirhumatismaux</term><term>Facteurs immunologiques</term><term>Glucocorticoïdes</term><term>Hydroxychloroquine</term><term>Prednisolone</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Dyspnée</term><term>Pneumopathies interstitielles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Male</term><term>Respiratory Function Tests</term><term>Rituximab</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Association de médicaments</term><term>Humains</term><term>Lupus érythémateux disséminé</term><term>Mâle</term><term>Rituximab</term><term>Résultat thérapeutique</term><term>Syndrome de Gougerot-Sjögren</term><term>Tests de la fonction respiratoire</term></keywords></textClass></profileDesc></teiHeader></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000153 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000153 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:21303472
|texte= Rituximab and lupus interstitial lung disease: friend or foe?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:21303472" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |